MedPath

Perioperative Salivary Alpha-amylase as a Predictor of Delirium After Lower Extremity Vascular Bypass Surgery

Recruiting
Conditions
Delirium
Lower Extremity
Salivary Alpha-amylase
Vascular Bypass Surgery
Interventions
Diagnostic Test: Salivary Alpha-amylase
Registration Number
NCT06242275
Lead Sponsor
Tanta University
Brief Summary

The aim of this study is to evaluate the role of salivary Alpha-amylase as a predictor biomarker of POD in elderly patients undergoing limb bypass surgery.

Detailed Description

Delirium is a neuropsychiatric syndrome that is characterized by the sudden onset of altered awareness, decreased ability to maintain attention, and disorders of the mental process. The pathophysiology of Postoperative delirium (POD) is related to postoperative neuroinflammation.

Biomarkers not only indicate a certain pathological state, but also provide information about disease activity and progression. Although several biomarkers are reported to predict POD, biomarkers with high sensitivity and specificity are still lacking.

Biochemical parameters associated with complement cascade (C3a, C3, C5a) and inflammatory response (IL-17A, IL-33, E-selectin, MMP9) were involved in neurocognitive regulation.

Salivary alpha amylase (SAA) enzyme is one of the most important enzyme compositions in the saliva that accounts for 40% to 50% of the total salivary proteins, and most of it is secreted from the parotid gland. SAA is locally produced by the highly differentiated epithelial acinar cells of the exocrine salivary glands, mostly of the parotid glands and plays an important role in carbohydrate hydrolysis.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Age ≥ 65 years.
  • Both sexes.
  • American Society of Anesthesiologists (ASA) physical status III.
  • Undergoing lower extremity vascular surgery under general anesthesia.
Exclusion Criteria
  • Patients who used any medication that could affect salivary glands (such as antihypertensive, antidepressants or antipsychotic drugs).
  • Inability to communicate.
  • History of psychiatric diseases or previous stroke
  • Previous history of pod.
  • Those with smoking and drinking habits.
  • Pregnant female.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
No Postoperative delirium (POD) groupSalivary Alpha-amylasePatients who will not develop postoperative delirium
Postoperative delirium (POD) groupSalivary Alpha-amylasePatients who will develop postoperative delirium
Primary Outcome Measures
NameTimeMethod
The accuracy of salivary alpha-amylase as a predictor of postoperative delirium3rd day postoperatively

The accuracy of salivary alpha-amylase will be measured by saliva samples which will be obtained using a saliva collection system and SAA level will be measured preoperatively, immediately postoperative, at the end of the 1st, 2nd, and 3rd postoperative days.

Secondary Outcome Measures
NameTimeMethod
Incidence of postoperative deliriumfirst 5 days after surgery

Incidence of postoperative delirium will be measured.

Correlation of salivary alpha-amylase with C-reactive protein24 hours postoperatively

Correlation of salivary alpha-amylase with C-reactive protein will be assessed.

Correlation of salivary alpha-amylase with average pain score24 hours postoperatively

Correlation of salivary alpha-amylase with average pain score will be assessed. Pain score will be assessed using numeric rating scale (NRS) score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable.

Correlation of salivary alpha-amylase with morphine consumption24 hours postoperatively

Correlation of salivary alpha-amylase with morphine consumption will be assessed.

Trial Locations

Locations (1)

Tanta University

🇪🇬

Tanta, El-Gharbia, Egypt

© Copyright 2025. All Rights Reserved by MedPath